<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal CancerChristos S. Karapetis, John Zalcberg, Shirin Khambata‐Ford et al.|New England Journal of Medicine|2008Cited by 3.6k
Cetuximab for the Treatment of Colorectal CancerDerek J. Jonker, Malcolm J. Moore, Chris J. O’Callaghan et al.|New England Journal of Medicine|2007Cited by 1.8k
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice GuidelinesGeorge D. Demetri, John Zalcberg, Robert S. Benjamin et al.|Journal of the National Comprehensive Cancer Network|2007Cited by 636
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialJean‐Yves Blay, Margaret von Mehren, César Serrano et al.|The Lancet Oncology|2020Cited by 406
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17Stephanie Yasmin Brule, Rachel Goodwin, Derek J. Jonker et al.|European Journal of Cancer|2015Cited by 337